Slide 1: Transforming Discovery of Therapeutics and Materials
Transforming Discovery of Therapeutics and Materials November 1, 2023
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this
Slide 3: 3Q23 Financial Highlights vs. 3Q22
3Q23 Financial Highlights vs. 3Q22 Three Months Ended September 30 2022 2023 % Change (in millions) Total revenue $37.0 $42.6 15.1% Software revenue $24.7 $28.9 17.2% Drug discovery revenue $12.3 $13.7 11% Gross profit $17.2 $23.6 37.4% Software gross margin 72% 76% Operating expenses $63.4 $79.8 26
Slide 4: 2023 Financial Guidance
2023 Financial Guidance (as of November 1, 2023) Year-to-Date Previous FY23 Revised FY23 Expectation FY22 Actual 3Q23 Guidance* Guidance* Total revenue $181.0 $142.5M – – Software revenue $135.6M $90.5M 15% - 18% Unchanged Drug discovery revenue $45.4M $52.1M $50-70M Unchanged Operating expense grow
Slide 5: Four-Quarter Trailing Average Quarterly Revenue Trend
Four-Quarter Trailing Average Quarterly Revenue Trend 5
Slide 6: Advancing Programs with Breakthrough Potential
Advancing Programs with Breakthrough Potential Status and anticipated next steps SGR-1505 (MALT1) SGR-2921 (CDC7) IND-enabling SGR-3515 studies (Wee1/Myt1) underway for • Clinically validated target for • Key cell cycle checkpoint for • Therapeutic potential across a SGR-2921 leukemias and lymphomas
Slide 7: Platform Validated by Advancing Collaboration Programs
Platform Validated by Advancing Collaboration Programs(1)(2) FDA FDA PROGRAM Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved PROGRAM Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved TIBSOVO* CNS IDHIFA* Autoimmune Disease Oncology Oncology Oncology Pulmonary Arterial Hypertension Antifu
Slide 8: Retained and Partnered Proprietary Programs
Retained and Partnered Proprietary Programs PROGRAM DISCOVERY PRECLINICAL PHASE I PROGRAM DISCOVERY PRECLINICAL CLINICAL RIGHTS SGR-1505 (MALT1) SOS1 Relapsed / Resistant RAS-Mutant Cancers Non-Hodgkin’s Lymphoma Undisclosed SGR-2921 (CDC7) Immunology Hematological Cancers and Solid Tumors Undisclos
Slide 9: Upcoming Milestones
Upcoming Milestones • Report initial SGR-1505 healthy volunteer data in 4Q23 • Present SGR-1505 and SGR-2921 preclinical data at ASH, December 9-14, 2023 • Submit IND for SGR-3515 in 1H24 • Pipeline Day, December 14, 2023 9
Slide 10: Transforming Discovery of Therapeutics and Materials
Transforming Discovery of Therapeutics and Materials November 1, 2023